Cigna Corporation (NYSE:CI) went lower by -0.62% to close at $ 138.67. The company exchanged total volume of 306.59 thousand shares throughout course of last trade however it holds an average trading capacity of 1.2 million shares. Shares of company began trading at $139.88 climbed to high of $141.48 touched the low of $138.53.
The company is trading above its 50-day moving averages of 127.74 and up from 200-day moving averages of 129.22. The firm has price to book ratio of 2.56 and its price to sale ratio was 0.91.
According to ZACKS data, different Brokerage Firms rated CI stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as BUY from 0 brokerage firms and recommended as Strong Buy by 6 brokerage firms.0 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 1 brokerage firms.5 brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of 2.17 based on consensus of the brokerage firms issuing ratings.
The average true range of Cigna Corporation’s (CI) is recorded at 4.01 and the relative strength index of the stock stands 63.72. The stock price is going above to its 52 week low with 20.55% and lagging behind from its 52 week high with -6.93%. Analyst recommendation for this stock stands at 1.90. A look on the firm performance, its monthly performance is 12.01% and a quarterly performance of 8.63%. The stock price is trading upbeat from its 200 days moving average with 5.23% and up from 50 days moving average with 8.05%.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) dropped -1.46% and closed the trade at $ 27.73. The company recorded a trading capacity of 0 shares below its three months average daily volume of 204.81 thousand shares. The stock’s 50-day moving average is noted at $23.10 and its 200-day moving average is stands at $21.36.
Additionally, the company has EPS of -2.07. The company has market capitalization of $594.31M.
ACRS stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as Buy from 0 brokerage firms and 4 brokerage firms say as Strong Buy. 0 brokerage firms have suggested Sell for the company. 0 brokerage firms have recommended as a Hold. Strong Sell rating was given by 0 brokerage firms. The Company has average brokerage recommendation (ABR) of 1 based on consensus of the ZACKS brokerage firms.
Aclaris Therapeutics, Inc.’s (ACRS) has price-to-cash ratio of 8.40 A look on the firm performance, its monthly performance is 26.26% and a quarterly performance of 30.11%. The stock price is moving up from its 20 days moving average with 21.28% and isolated positively from 50 days moving average with 17.82%.